Research programme: next-generation hepatitis C virus therapeutics - Shire/Wyeth

Drug Profile

Research programme: next-generation hepatitis C virus therapeutics - Shire/Wyeth

Latest Information Update: 22 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ViroPharma; Wyeth
  • Class Benzofurans; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 16 Apr 2008 Discontinued - Preclinical for Hepatitis C in USA (unspecified route)
  • 16 Feb 2005 A potential drug candidate (HCV 796) has been selected for further development
  • 07 Jan 2005 Wyeth has filed an IND with the FDA in USA for Hepatitis C
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top